Eli Lilly and Co
GEHC stock finally gets some respect after earnings. Those betting against it got slammed
Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. That coupled with management’s upbeat view of this year propelled shares up more than 13% to over $83 each at session highs. That was their highest level since July 2023. The Club stock closed just under $82. Total […]
Read More
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. The initial study […]
Read More
Wall Street says Big Tech needs to take a breather after huge run. Here's our take
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning is […]
Read More
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. Mike Blake | Reuters Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. […]
Read More
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. Victoria Klesty | Reuters Novo Nordisk‘s parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection […]
Read More
Wall Avenue heads into the 7 days in advance worrying the rally to document highs is managing out of steam
Wall Street continues to climb a wall of fret even as investors deliberate how significantly more time equities can preserve their report operate. The stock rally continued on Friday , with the main averages each individual advancing additional than 1% for the week, buoyed by robust final results from Meta and Amazon, as effectively as […]
Read More
Here are Jim Cramer’s rapid-fire takeaways on 6 stocks in the news Friday
Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember, our […]
Read More
January was great for stocks — here are our top 5 performers for the month
Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. Source
Read More
Want to cash in on the fat-reduction drug increase? Morgan Stanley names 4 global shares
Drug makers these kinds of as Eli Lilly and Novo Nordisk have been very hot favorites among the traders in the previous 12 months, specified the favourable reception to their pounds-decline medications. “The uptake of GLP-1 (glucagon-like-pepitide-1) course AOMs (anti-weight problems drugs) has been unexpectedly robust, specially in the U.S. the place the medicines are […]
Read More
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Norway’s giant wealth fund, the world’s largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly […]
Read More